# Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Study · id `cardio:ct-nct02094963` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02094963](<https://clinicaltrials.gov/study/NCT02094963>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02094963

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

## Technical summary

Registry record NCT02094963. Randomized; no masking; primary purpose treatment. Start 2014-07-05 (actual); primary completion 2018-11-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 800 participants (enrolled count; ClinicalTrials.gov record NCT02094963, source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)
- Started: 2014-07-05 (actual) (ClinicalTrials.gov record NCT02094963, source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)
- Primary completion: 2018-11-01 (actual) (ClinicalTrials.gov record NCT02094963, source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)
- Completion: 2018-11-01 (actual) (ClinicalTrials.gov record NCT02094963, source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02094963, source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02094963-2018-11-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management
- Acronym: TICA KOREA
- Condition: Acute Coronary Syndrome
- Condition: Myocardial Ischemia
- Condition: Heart Diseases
- Condition: Cardiovascular Diseases
- Condition: Angina Pectoris
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Clopidogrel
- Lead sponsor: Seung-Jung Park
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Seung-Jung Park (`cardio:org-seung-jung-park`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial (`cardio:pubmed-31553203`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6020320310b702486a54fee260b02a6d98424389abf72c3bbd3b22ca16571d4c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
